TransCode Therapeutics

NASDAQ: RNAZ ↗$5.93 USD~$15M (small-cap, July 2026) MCAP

#Metastatic Cancer #ctDNA-Positive Colorectal Cancer #RNA Interference (siRNA) Therapeutics #Nanoparticle Drug Delivery #Antisense Oligonucleotide Delivery

TransCode Therapeutics is a clinical-stage oncology company developing a pipeline of RNA-targeted therapeutics using its proprietary TTX (Therapeutic Targeting and Transport) nanoparticle delivery platform, which is designed to enable systemic delivery of siRNA, antisense, and other oligonucleotide payloads to metastatic tumors. The lead program, TTX-MC138, is being studied in metastatic cancer, with Phase 1a completion announced in June 2026 (no DLTs, durable disease stabilization) and a Phase 2a trial in ctDNA-positive colorectal cancer initiated in May 2026.

Company Info

Sector:Biotechnology / RNA Therapeutics & Targeted Delivery

Headquarters:Boston, Massachusetts, USA

Founded:2016

Website:www.transcodetherapeutics.com/

Upcoming Milestones & Key Dates

Q3 2026

Corporate

Q2 2026 financial results and Phase 2a trial update

Clinical Development Pipeline

TTX-MC138

Target: MicroRNA-10b (miR-10b) inhibition via TTX nanoparticle platform

Metastatic cancer (Phase 1a complete June 2026) and ctDNA-positive colorectal cancer (Phase 2a initiated May 2026)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TTX-RIGA

Target: RNA agonist delivered via TTX nanoparticle platform

Cancer immunotherapy — combination with immune checkpoint inhibitors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TTX-Disrupter

Target: RNA-targeted TTX platform

Preclinical — undisclosed oncology targets

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Thomas A. Fitzgerald

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

Boston, MA

Apply Now →